SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE TO/A
(Amendment No. 6)
(Rule 14d-100)
 
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934

 
BRISTOL-MYERS SQUIBB COMPANY
(Name of Subject Company and Filing Person (Issuer and an Offeror))
MEAD JOHNSON NUTRITION COMPANY
(Name of Filing Person (Affiliate of the Issuer and an Offeror))

Common Stock, $0.10 Par Value
(Title of Class of Securities)
110122108
(CUSIP Number of Class of Securities)

Sandra Leung, Esq.
Senior Vice President, General
Counsel & Secretary
P. Joseph Campisi, Jr., Esq.
Vice President & Senior Counsel
Bristol-Myers Squibb Company
345 Park Avenue
New York, New York 10154
(212) 546-4000	 	William P’Pool, Esq.
Mead Johnson Nutrition Company
2701 Patriot Blvd.
Glenview, Illinois 60026
(847) 832-2420	
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications on Behalf of Filing Persons)

Copies to:

Ronald Cami, Esq.
Cravath, Swaine & Moore LLP
Worldwide Plaza
825 Eighth Avenue
New York, NY 10019-7475
(212) 474-1000	 	David A. Schuette, Esq.
Mayer Brown LLP
71 S. Wacker Dr.
Chicago, IL 60606
(312) 782-0600	

CALCULATION OF FILING FEE

 	
Transaction Valuation (1)	 	Amount of Filing Fee (2)	
$7,687,400,000	 	$428,957	

(1)	This valuation assumes the exchange of up to 170,000,000 shares of class A common stock, par value $0.01 per share, of Mead Johnson Nutrition Company, a Delaware corporation, for shares of common stock, par value $0.10 per share, of Bristol-Myers Squibb Company, a Delaware Corporation. Estimated solely for purposes of calculating the filing fee pursuant to Rule 0-11(a)(4) under the Securities Exchange Act of 1934, based on the product of (i) $45.22, the average of the high and low sale prices of MJN common stock on The New York Stock Exchange on November 13, 2009 and (ii) 170,000,000, the maximum number of shares of MJN common stock to be exchanged in the exchange offer.	
 
(2)	Computed in accordance with Rule 0-11(a)(4) under the Securities Exchange Act of 1934.	
 
þ	Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.	
Amount Previously Paid: $428,957.00
Form or Registration No.: Registration Statement on Form S-4 (No. 333-163126)
Filing Party: Mead Johnson Nutrition Company
Date Filed: November 16, 2009
 
¨	Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.	
Check the appropriate boxes below to designate any transaction to which the statement relates:
 
¨	third-party tender offer subject to Rule 14d-1	
 
þ	issuer tender offer subject to Rule 13e-4	
 
¨	going-private transaction subject to Rule 13e-3	
 
¨	amendment to Schedule 13D under Rule 13d-2	
Check the following box if the filing is a final amendment reporting the results of the tender offer: þ
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
 
¨	Rule 13e-4(i) (Cross-Border Issuer Tender Offer)	
 
¨	Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)	

 

 
This Amendment No. 6 (this “ Amendment No. 6 ”) amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission (“ SEC ”) by Bristol-Myers Squibb Company (“ BMS ”) on November 16, 2009, as amended by Amendment No. 1 to the Tender Offer Statement on Schedule TO, filed with the SEC on November 25, 2009, Amendment No. 2 to the Tender Offer Statement on Schedule TO, filed with the SEC on December 7, 2009, Amendment No. 3 to the Tender Offer Statement on Schedule TO, filed with the SEC on December 11, 2009, Amendment No. 4 to the Tender Offer Statement on Schedule TO, filed with the SEC on December 16, 2009 and Amendment No. 5 to the Tender Offer Statement on Schedule TO, filed with the SEC on December 18, 2009 (as so amended, the “ Schedule TO ”). This Schedule TO relates to the offer by BMS to exchange up to 170,000,000 shares of class A common stock, par value $0.01 per share (“ MJN common stock ”) of MJN, in the aggregate, for shares of BMS common stock, par value $0.10 per share (“ BMS common stock ”), upon the terms and subject to the conditions set forth in the Prospectus, dated December 15, 2009 (the “ Prospectus ”) and the related Letter of Transmittal (which, together with any amendments or supplements thereto, collectively constitute the “ Exchange Offer ”). In connection with the Exchange Offer, MJN has filed under the Securities Act of 1933, as amended (the “ Securities Act ”), a registration statement on Form S-4 (Registration No. 333-163126) (the “ Registration Statement ”) to register the shares of MJN common stock offered in exchange for shares of BMS common stock tendered in the Exchange Offer. The information set forth in the Prospectus and the Letter of Transmittal is incorporated herein by reference in response to all the items of this Schedule TO, except as otherwise set forth below. Except as specifically provided herein, this Amendment No. 6 does not modify any of the information previously reported on the Schedule TO.
 
Item 4.	Terms of the Transaction.	
Item 4(a) of the Schedule TO, which incorporates by reference the information contained in the Exchange Offer, is hereby amended and supplemented by adding the following thereto:
The Exchange Offer expired at 12:00 midnight, New York City time, on December 17, 2009. BMS accepted for exchange 269,285,601 shares of BMS common stock in exchange for the 170,000,000 shares of MJN common stock owned by BMS. Each share of BMS common stock accepted for exchange by BMS was exchanged for 0.6313 shares of MJN common stock.
Because the Exchange Offer was oversubscribed, BMS accepted only a portion of the shares of BMS common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Stockholders who owned less than 100 shares of BMS common stock, or an “odd-lot”, who validly tendered all of their shares, could elect not to be subject to proration, in accordance with the terms of the Exchange Offer. All shares tendered by eligible electing odd-lot stockholders have been accepted. The final proration factor of 53.8954842% was applied to all other tendered shares of BMS common stock to determine the number of such shares that would be accepted.
Based on the final count by the exchange agent, BNY Mellon Shareowner Services, the results of the Exchange Offer are as follows:

Total number of shares of BMS common stock tendered	  	499,484,935	
Shares tendered that were subject to proration	  	499,298,888	
“Odd-lot” shares tendered that were not subject to proration	  	186,047	
Total number of shares of BMS common stock accepted	  	269,285,601	
On December 23, 2009, BMS and MJN issued a press release announcing the final results of the Exchange Offer, a copy of which is attached as Exhibit (a)(4)(vi) hereto and is incorporated herein by reference.
 
Item 12.	Exhibits.	
Item 12 of the Schedule TO is hereby amended and supplemented by adding the following thereto:
(a)(4)(vi) Press Release by Bristol-Myers Squibb Company and Mead Johnson Nutrition Company announcing the final results of the exchange offer dated December 23, 2009.
 
2

SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: December 23, 2009

BRISTOL-MYERS SQUIBB COMPANY	
		
By:	 	/ S /  S ANDRA L EUNG        	
	 	 	
Name: 	 	Sandra Leung	
Title:	 	Senior Vice President, General Counsel and Secretary	

			
MEAD JOHNSON NUTRITION COMPANY	
		
By:	 	/ S /  S TANLEY B URHANS        	
	 	 	
Name: 	 	Stanley Burhans	
Title:	 	Vice President and Controller	
 
3

EXHIBIT INDEX

 Exhibit
Number	  	Description	
		
(a)(1)(i)	  	Form of Letter of Transmittal (Book Entry) (incorporated by reference to Exhibit 99.1 to Mead Johnson Company’s Registration Statement on Form S-4 (Registration No. 333-163126), filed with the Securities and Exchange Commission on November 16, 2009, as amended by Amendment No. 1 to the Registration Statement on Form S-4 filed with the SEC on November 25, 2009, Amendment No. 2 to the Registration Statement on Form S-4 filed with the SEC on December 7, 2009 and Amendment No. 3 to the Registration Statement on Form S-4 filed with the SEC on December 11, 2009 (as so amended, the “ Registration Statement ”)).	
		
(a)(1)(ii)	  	Form of Letter of Transmittal (Certificates) (incorporated by reference to Exhibit 99. 2 to the Registration Statement)	
		
(a)(1)(iii)	  	Instructions for Letter of Transmittal (incorporated by reference to Exhibit 99. 3 to the Registration Statement)	
		
(a)(1)(iv)	  	Form of Notice of Guaranteed Delivery (incorporated by reference to Exhibit 99.4 to the Registration Statement).	
		
(a)(1)(v)	  	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to Exhibit 99.5 to the Registration Statement).	
		
(a)(1)(vi)	  	Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (incorporated by reference to reference to Exhibit 99.6 the Registration Statement).	
		
(a)(1)(vii)	  	Form of Notice of Withdrawal (incorporated by reference to Exhibit 99.7 to the Registration Statement).	
		
(a)(4)(i)*	  	Press Release by Bristol-Myers Squibb Company announcing the commencement of the exchange offer dated November 15, 2009.	
		
(a)(4)(ii)	  	Prospectus, dated December 15, 2009, filed with the Securities and Exchange Commission on December 16, 2009.	
		
(a)(4)(iii)**	  	Press Release by Bristol-Myers Squibb Company and Mead Johnson Nutrition Company announcing the amendment and extension of the exchange offer dated December 4, 2009.	
		
(a)(4)(iv)***	  	Press Release by Bristol-Myers Squibb Company and Mead Johnson Nutrition Company announcing that Bristol-Myers Squibb Company has set the exchange ratio for its exchange offer dated December 16, 2009.	
		
(a)(4)(v)****	  	Press Release by Bristol-Myers Squibb Company and Mead Johnson Nutrition Company announcing the preliminary results of the exchange offer dated December 18, 2009.	
		
(a)(4)(vi)	  	Press Release by Bristol-Myers Squibb Company and Mead Johnson Nutrition Company announcing the final results of the exchange offer dated December 23, 2009.	
		
(h)(i)	  	Opinion of Cravath, Swaine & Moore LLP regarding certain tax consequences of the exchange offer (incorporated by reference to Exhibit 8.1 to the Registration Statement).	
 
*	Previously filed with the Securities and Exchange Commission on the Tender Offer Statement on Schedule TO filed on November 16, 2009.	
**	Previously filed with the Securities and Exchange Commission on Amendment No. 2 to the Tender Offer Statement on Schedule TO filed on December 7, 2009.	
***	Previously filed with the Securities and Exchange Commission on Amendment No. 4 to the Tender Offer Statement on Schedule TO filed on December 16, 2009.	
****	Previously filed with the Securities and Exchange Commission on Amendment No. 5 to the Tender Offer Statement on Schedule TO filed on December 18, 2009.	
 
4

Exhibit (a)(4)(vi)

Bristol-Myers Squibb and Mead Johnson Announce
Final Results of the Exchange Offer
(NEW YORK, December 23, 2009) — Bristol-Myers Squibb Company (NYSE: BMY) and Mead Johnson Nutrition Company (NYSE: MJN) announced today the final results of the offer by Bristol-Myers Squibb to exchange up to 170,000,000 shares of common stock of Mead Johnson for outstanding shares of Bristol-Myers Squibb common stock that were validly tendered and not validly withdrawn.
The offer expired at 12:00 midnight, New York City time, on December 17, 2009. Under the terms of the offer, Bristol-Myers Squibb accepted 269,285,601 shares of Bristol-Myers Squibb common stock in exchange for 170,000,000 shares of Mead Johnson common stock owned by Bristol-Myers Squibb.
Each share of Bristol-Myers Squibb common stock accepted for exchange by Bristol-Myers Squibb was exchanged for 0.6313 shares of Mead Johnson common stock. Any fractional shares of Mead Johnson common stock will be aggregated and sold, and the net cash proceeds will be distributed to tendering stockholders with fractional interests.
Because the offer was oversubscribed, Bristol-Myers Squibb accepted tendered shares on a pro rata basis in proportion to the number of shares tendered. Stockholders who owned less than 100 shares of Bristol-Myers Squibb common stock, or an “odd-lot”, who validly tendered all of their shares, could elect not to be subject to proration in accordance with the terms of the exchange offer. All shares tendered by eligible electing odd-lot stockholders have been accepted. The final proration factor of 53.8954842% was applied to all other tendered shares of Bristol-Myers Squibb common stock to determine the number of such shares that would be accepted from each tendering stockholder.
Based on the final count by the exchange agent, BNY Mellon Shareowner Services, the results of the exchange offer are as follows:

Total number of shares of Bristol-Myers Squibb common stock tendered	  	499,484,935	
Shares tendered that were subject to proration	  	499,298,888	
“Odd-lot” shares tendered that were not subject to proration	  	186,047	
Total number of shares of Bristol-Myers Squibb common stock accepted	  	269,285,601	

The exchange agent is expected to deliver shares of Mead Johnson common stock as follows: (1) with respect to shares tendered through the Depository Trust Company, to the account of DTC on December 23, 2009, so that DTC can credit the relevant DTC participant (and such participant can credit its respective account holders promptly thereafter) and (2) with respect to shares tendered outside DTC, to direct registered accounts of the respective holders by December 29, 2009. The exchange agent is expected to mail or deliver checks in lieu of a fractional share of Mead Johnson common stock thereafter.
Citigroup Global Markets Inc., Goldman, Sachs & Co. and Morgan Stanley & Co. Incorporated are serving as the dealer managers for the exchange offer.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.
About Mead Johnson
Mead Johnson, a global leader in pediatric nutrition, develops, manufactures, markets and distributes more than 70 products in 50 markets worldwide. The company’s mission is to create nutritional brands and products trusted to give infants and children the best start in life. The Mead Johnson name has been associated with science-based pediatric nutrition products for over 100 years. The company’s “Enfa” family of brands, including Enfamil ® infant formula, is the world’s leading brand franchise in pediatric nutrition. For more information, go to www.meadjohnson.com.
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements”. All statements in this press release, other than those relating to historical information or current condition, are forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the exchange offer will be completed, or if it is completed, that it will close within the anticipated time period. Bristol-Myers Squibb and Mead Johnson undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contacts
Media: Brian Henry, 609-252-3337, brian.henry@bms.com
Investors: John Elicker, 609-252-4611, john.elicker@bms.com